US EditionPublished • loading... • Updated
Heart benefits fade after stopping GLP-1 medications
A study of over 333,000 adults found that stopping GLP-1 drugs like Ozempic raises cardiovascular risk, reversing benefits gained from continuous use over three years.
- Published on Wednesday in BMJ Medicine, a Washington University School of Medicine study found short gaps in GLP-1 treatment raise risks of heart attack, stroke and death, tracking more than 333,000 adults with Type 2 diabetes, mostly on Novo Nordisk's Ozempic.
- Roughly one in eight U.S. adults take GLP-1 drugs, but discontinuation rates run as high as 36% to 81% due to access problems and side effects like nausea and vomiting.
- Analysis showed quitting for six months raised risk by 4% and a two-year gap pushed it to 22%, while patients who stayed on GLP-1s saw an 18% reduction in cardiovascular risk, Washington University said.
- Al-Aly warned that stopping GLP-1s causes cardiovascular protection to vanish, calling it a 'metabolic whiplash' and urging providers and patients to stay on treatment 'for the long haul'.
- Policy moves such as Medicare covering weight-loss drugs could ease access, as Eli Lilly pursues employer-coverage efforts and drugmakers develop next-generation treatments with fewer side effects.
Insights by Ground AI
34 Articles
34 Articles
How long should you take GLP-1 drugs? Study links longer use to lower heart risk
Continuous use of GLP-1 receptor agonists in adults with type 2 diabetes was associated with a lower risk of major cardiovascular events compared with sulfonylureas, with benefits increasing over time. Discontinuation or interruption was associated with a progressive loss of this protective effect, with risks approaching those of comparator therapy.
·United States
Read Full Article
Does stopping GLP-1 drugs raise heart risk?
Heart benefits of GLP 1 drugs may fade after stopping One of the stories in the pool warns that cardiovascular benefits linked to injected GLP 1 medications—commonly prescribed under brand names such as Wegovy, Ozempic, Mounjaro, and Zepbound—may diminish after people stop taking them. What…
Coverage Details
Total News Sources34
Leaning Left1Leaning Right0Center29Last UpdatedBias Distribution97% Center
Bias Distribution
- 97% of the sources are Center
97% Center
C 97%
Factuality
To view factuality data please Upgrade to Premium
